Sugentech, Inc. Logo

Sugentech, Inc.

An in-vitro diagnostics company that develops and commercializes diagnostic solutions.

253840 | KO

Overview

Corporate Details

ISIN(s):
KR7253840003
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노2로 206 사무동2층 수젠텍, 대전광역시

Description

Sugentech, Inc. is an in-vitro diagnostics (IVD) company that develops and commercializes diagnostic solutions by integrating biotechnology, nanotechnology, and information technology. The company's product portfolio serves diverse healthcare settings, from large hospitals and laboratories to smaller clinics and home users. Key offerings include automated multi-immunoblot systems, point-of-care testing (POCT) platforms, and self-diagnostic kits for personal use, such as ovulation and pregnancy tests. Sugentech leverages proprietary technologies in developing high-level antibodies and advanced nanoparticles to create highly sensitive and precise immunochemical assays, underpinning its digital healthcare diagnostic platform for personalized medicine.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-11-12 00:00
신규시설투자등
Korean 8.9 KB
2021-11-11 00:00
단일판매ㆍ공급계약체결
Korean 9.5 KB
2021-10-27 00:00
단일판매ㆍ공급계약체결
Korean 9.5 KB
2021-10-18 00:00
전환가액의조정(제2회차)
Korean 10.8 KB
2021-10-18 00:00
기타경영사항(자율공시)(전환우선주 전환가액 조정)
Korean 9.5 KB
2021-09-14 00:00
단일판매ㆍ공급계약체결
Korean 9.5 KB
2021-09-02 00:00
단일판매ㆍ공급계약체결
Korean 9.5 KB
2021-08-18 00:00
단일판매ㆍ공급계약체결
Korean 9.5 KB
2021-08-13 00:00
[기재정정]사업보고서 (2020.12)
Korean 2.0 MB
2021-08-13 00:00
반기보고서 (2021.06)
Korean 1.5 MB
2021-07-20 00:00
단일판매ㆍ공급계약체결
Korean 9.5 KB
2021-07-16 00:00
증권발행결과(자율공시)(제3자배정 유상증자-기명식 전환우선주)
Korean 6.0 KB
2021-07-16 00:00
증권발행결과(자율공시)(제2회 무기명 이권부 무보증 사모 전환사채)
Korean 6.1 KB
2021-07-09 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 70.6 KB
2021-07-09 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 68.1 KB

Automate Your Workflow. Get a real-time feed of all Sugentech, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sugentech, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sugentech, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.